BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive gene expression tests to monitor immune-mediated conditions, today announced that Blue Shield of California considers AlloMap® “medically necessary” for monitoring heart transplant rejection more than one year post-transplant. By assuring coverage of AlloMap for its eligible patients, Blue Shield of California recognizes the clinical utility of this non-invasive method of determining the risk of rejection in stable heart transplant recipients.
